XBiotech Inc. (FRA:4XB)
Germany
· Delayed Price · Currency is EUR 2.000
-0.060 (-2.91%)
At close: Dec 5, 2025
XBiotech Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -29.16 | -38.53 | -24.56 | -32.9 | -17.41 | -11.22 | Upgrade
|
| Depreciation & Amortization | 1.75 | 1.75 | 1.74 | 2.61 | 2.65 | 2.24 | Upgrade
|
| Stock-Based Compensation | 4.09 | 1.75 | 3.26 | 5.06 | 4.46 | 12.58 | Upgrade
|
| Other Operating Activities | 1.94 | 5.53 | -1.89 | 2.8 | - | - | Upgrade
|
| Change in Accounts Receivable | - | - | - | - | 4.11 | -4.11 | Upgrade
|
| Change in Accounts Payable | -0.53 | -0.36 | 0.09 | 0.36 | -0.51 | -0.33 | Upgrade
|
| Change in Unearned Revenue | - | - | - | - | - | -4.5 | Upgrade
|
| Change in Income Taxes | 0.21 | -0.11 | 0.6 | 8.71 | -2.17 | -6.51 | Upgrade
|
| Change in Other Net Operating Assets | -1.81 | -0.99 | 2.09 | -0.65 | 76.91 | -3.98 | Upgrade
|
| Operating Cash Flow | -23.51 | -30.96 | -18.73 | -14.82 | 69.45 | -65.15 | Upgrade
|
| Capital Expenditures | -0.34 | -1.3 | -0.36 | -0.59 | -3.53 | -3.73 | Upgrade
|
| Investment in Securities | - | - | 61.86 | -63.31 | - | - | Upgrade
|
| Investing Cash Flow | -0.34 | -1.3 | 61.5 | -63.89 | -3.53 | -3.73 | Upgrade
|
| Short-Term Debt Issued | - | 10.25 | - | - | - | - | Upgrade
|
| Total Debt Issued | 0.25 | 10.25 | - | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -10 | 10.25 | - | - | - | - | Upgrade
|
| Issuance of Common Stock | 0.03 | 0.2 | 0.01 | - | 8 | 10.28 | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | - | -420 | Upgrade
|
| Common Dividends Paid | - | - | - | - | -75 | - | Upgrade
|
| Other Financing Activities | - | - | -0.01 | - | - | - | Upgrade
|
| Financing Cash Flow | -9.97 | 10.45 | -0.01 | - | -67.01 | -409.72 | Upgrade
|
| Foreign Exchange Rate Adjustments | -1.94 | -5.53 | -0.05 | -0.96 | 0.71 | 1.37 | Upgrade
|
| Net Cash Flow | -35.75 | -27.35 | 42.72 | -79.68 | -0.38 | -477.23 | Upgrade
|
| Free Cash Flow | -23.85 | -32.27 | -19.09 | -15.41 | 65.92 | -68.88 | Upgrade
|
| Free Cash Flow Margin | - | - | - | -384.26% | 358.38% | -156.55% | Upgrade
|
| Free Cash Flow Per Share | -0.78 | -1.06 | -0.63 | -0.51 | 2.19 | -2.23 | Upgrade
|
| Cash Interest Paid | 0.49 | 0.4 | - | - | - | - | Upgrade
|
| Cash Income Tax Paid | 0.09 | 0.09 | 0.14 | - | - | 54.09 | Upgrade
|
| Levered Free Cash Flow | -18.46 | -26.29 | -16.1 | -6.33 | 66 | -143.38 | Upgrade
|
| Unlevered Free Cash Flow | -18.27 | -25.79 | -16.1 | -6.33 | 66 | -143.38 | Upgrade
|
| Change in Working Capital | -2.12 | -1.46 | 2.72 | 7.6 | 79.75 | -68.75 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.